Status:
TERMINATED
COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study
Lead Sponsor:
General Practitioners Research Institute
Collaborating Sponsors:
Huisartsenzorg Drenthe
Conditions:
Covid19
Corona Virus Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The COVID-19 coronavirus has led to a global pandemic of respiratory diseases with an increase in hospitalization and death risk. To keep COVID-19 manageable for healthcare, early treatment is urgentl...
Eligibility Criteria
Inclusion
- Age ≥18 years
- A positive test for SARS-CoV-2
- A GP consultation for deteriorating COVID-19 symptoms
- Additional inclusion criteria in order to be eligible for randomization to the trial:
- \- Exercise-induced desaturation, defined as SpO2\<92% (\<90% for COPD patients) and/or an absolute drop of ≥4% in SpO2 after a 1-minute sit-to-stand test
- OR
- \- SpO2\<92% (\<90% for COPD patients) in rest with GP's and patient's shared decision to keep patient at home despite this in itself being an indication for referral to hospital
Exclusion
- Inability to understand and sign the written consent form
- Inability to perform saturation measurements or sit-to-stand test
- Not willing to be admitted to hospital
- On the discretion of the recruiting clinician if he or she deems a patient not eligible
- The following criterion will be used to exclude patients from randomization to the trial:
- Contra-indication for dexamethasone
Key Trial Info
Start Date :
February 16 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 23 2021
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT04746430
Start Date
February 16 2021
End Date
April 23 2021
Last Update
May 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GPRI
Groningen, Netherlands